JI Linong , Chairman of Diabetes and Metabolic Disease Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Director of Endocrinology and Metabolism Department,Peking University People's Hospital
14:00 - 14:30
主题报告1
Keynote Speech 1
心血管-肾脏-代谢三联症 新药研发及临床管理思考
Reflections on the R&D of New Drugs and Clinical Management of Cardiovascular-Kidney-Metabolic Diseases
纪立农 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会主任委员,北京大学人民医院内分泌科主任
JI Linong , Chairman of Diabetes and Metabolic Disease Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Director of Endocrinology and Metabolism Department,Peking University People's Hospital
14:30 - 14:55
主题报告2
Keynote Speech 2
创新药医保准入与支付标准考量要点思考
Considerations on Key Points for the Medical Insurance Access and Payment Standards of Innovative Drugs
金春林 上海市卫生和健康发展研究中心主任
JIN Chunlin , Director of Shanghai Health Development Research Center
14:55 - 15:20
主题报告3
Keynote Speech 3
代谢疾病/减重药物市场趋势与行业分析
Trends and Analysis for Metabolic/Anti-Obesity Drugs
贺菊颖 中信建投证券医药行业首席分析师
HE Juying , Head of Healthcare Equity Research at China Securities
15:20 - 15:50
主题讨论1
Panel 1
如何协同推进代谢药物创新可持续发展
How to Advance the Sustainable Development of Innovative Drugs for Metabolic Diseases Through Collaboration
JI Linong , Chairman of Diabetes and Metabolic Disease Clinical Research Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Director of Endocrinology and Metabolism Department,Peking University People's Hospital
Panelists
广州市卫生健康委员会 , Guangzhou Municipal Health Commission
Guangzhou Municipal Health Commission ,
金春林 , 上海市卫生和健康发展研究中心主任
JIN Chunlin , Director of Shanghai Health Development Research Center
朱文静 , 勃林格殷格翰心肾代谢疾病治疗领域医学负责人
Julia ZHU , Therapeutic Area Head of Cardio-Renal-Metabolic diseases in Medicine, Boehringer Ingelheim
袁清慧 , 中信建投证券制药及生物科技组首席分析师
YUAN Qinghui , Head of Pharmaceutical and Biotechnology Industry Equity Research at China Securities
15:50 - 17:40
第二阶段:聚焦热点——肥胖/MASH疾病管理与临床开发趋势
Session II: Research Hotspot - Trends in Disease Management and R&D for Obesity/MASH
Moderator
姜宏卫 , 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会委员,河南科技大学第一附属医院副院长
JIANG Hongwei , Member of Diabetes and Metabolic Disease Clinical Research Committee of PhIRDA Vice President of the First Affiliated Hospital of Henan University of Science & Technology
15:50 - 16:20
主题报告4
Keynote Speech 4
聚焦研发新靶点,审视抗肥胖/MASH药物临床应用前景
Focusing on the Progress and Clinical Application Prospects of New Drugs for Obesity and MASH
饶慧瑛 北京大学肝病研究所所长
RAO Huiying , Director of Peking University Hepatology Institute
16:20 - 16:45
主题报告5
Keynote Speech 5
从基础到临床,探索肥胖症与肝脏疾病密切关联性探讨
From Bench to Bed, Exploring the Relationship between Obesity and Fatty Liver Disease
邹显彤 北京大学人民医院副研究员
ZOU Xiantong , Assistant Professor of Peking University
16:45 - 17:10
主题报告6
Keynote Speech 6
面对代谢疾病临床开发的机遇与挑战
The Challenges and Opportunities of Clinical Development for Metabolic Diseases
How to Optimize the Clinical Development and Disease Management of Obesity/MASH Diseases Through Multi-Party Collaboration
Moderator
姜宏卫 , 中国药促会糖尿病与代谢性疾病药物临床研究专业委员会委员,河南科技大学第一附属医院副院长
JIANG Hongwei , Member of Diabetes and Metabolic Disease Clinical Research Committee of PhIRDA Vice President of the First Affiliated Hospital of Henan University of Science & Technology
Panelists
饶慧瑛 , 北京大学肝病研究所所长
RAO Huiying , Director of Peking University Hepatology Institute
李延兵 , 中山大学附属第一医院内分泌科主任
LI Yanbing , Director of the Department of Endocrinology, First Affiliated Hospital of Sun Yat-sen University